May 06, 2024 9:05am EDT Lexaria Announces New Research Program to Evaluate Mode of Action and Performance of DehydraTECH-GLP-1 Drugs
Apr 30, 2024 3:40pm EDT Lexaria to Receive $4.7 Million Gross Proceeds in Warrant Exercise and Issuance
Mar 01, 2024 8:20am EST Lexaria Announces FDA Clearance for its Planned U.S. Phase 1b Hypertension Clinical Trial
Feb 16, 2024 4:05pm EST Lexaria Announces Closing of $3.6 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules